【摘要】 目的探讨微移植联合抗血管生成化疗治疗非小细胞肺癌的临床疗效及不良反应。方法选取2015年1月至2016年5月山西医科大学第二医院就诊的104例非小细胞肺癌患者,根据其对微移植及抗血管生成化疗治疗的接受度分为微移植联合抗血管生成化疗组51例和单纯抗血管生成化疗组53例,微移植联合抗血管生成化疗组接受微移植+抗血管生成化疗治疗,单纯抗血管生成化疗组仅进行单纯抗血管生成化疗。采用χ2检验比较临床治疗有效率、疾病控制率、生活质量总改善率以及不良反应发生率的组间差异。结果微移植联合抗血管生成化疗组的治疗有效率高于单纯抗血管生成化疗组(70.6%vs 50.9%),差异具有统计学意义(χ2=4.200,P<0.05);微移植联合抗血管生成化疗组的疾病控制率高于单纯抗血管生成化疗组(94.1%vs 81.1%),2组比较差异有统计学意义(χ2=4.007,P<0.05);微移植联合抗血管生成化疗组的生活质量改善率高于单纯抗血管生成化疗组(90.2%vs 75.5%),差异具有统计学意义(χ2=3.937,P<0.05);2组患者的不良反应(包括发热、消化道症状、肝肾功能损害、骨髓抑制等)发生率差异无统计学意义(P>0.05)。结论微移植联合抗血管生成化疗治疗非小细胞肺癌可以提高临床治疗效果,改善患者生活质量。更多还原

【Abstract】 Objective To evaluate the clinical efficacy and adverse reactions of microtransplantation combined with antiangiogenic chemotherapy in the treatment of patients with non-small cell lung cancer(NSCLC). Methods From January 2015 to May 2016, 104 patients with NSCLC treated at our hospital were divided into an observation group(51 cases) and a control group(53 cases). The observation group received microtransplantation combined with antiangiogenic chemotherapy, while the control group received antiangiogenic chemotherapy only. The short-term clinical effect, the rate of disease control, the quality of life, and adverse reactions were compared between the two groups. Results The effective rate in the observation group was significantly higher than that in the control group(70.6% vs 50.9,χ2=4.200,P < 0.05). The disease control rate was also significantly higher in the observation group than in the control group(94.1% vs81.1%, χ2=4.007, P < 0.05). The rate of quality of life improvement was significantly higher in the observation group than in the control group(90.2% vs 75.5%, χ2=3.937, P < 0.05). There was no significant difference in the rate of adverse reactions(including fever, gastrointestinal symptoms, liver and kidney dysfunction, and bone marrow suppression) between the two groups(P > 0.05). Conclusion Microtransplantation combined with antiangiogenic chemotherapy can effectively improve the therapeutic effects and quality of life in patients with NSCLC.更多还原